Endometrial cancer: trials for referral
437 open trials in the registries we read. Each row links to its registry record.
Registry data only. Frontlight does not judge whether a patient can take part: the trial team decides.
Where the open trials are
Type a city to sort by distance. The distance is worked out in your browser; the city is not sent anywhere.
400 trials shown · Showing the 400 most recently updated of 437 open trials.
Phase 125 sites
RecruitingSpain, France, United Kingdom, United States
NCT06515613
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
Context Therapeutics Inc.
Registry updated 10 Nov 2026
Registry record: ClinicalTrials.govPhase 127 sites
RecruitingSpain, Georgia, United States
NCT07503808
A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types
IDEAYA Biosciences
Registry updated 10 Nov 2026
Registry record: ClinicalTrials.govPhase 3235 sites
RecruitingArgentina, Austria, Australia, Belgium, Brazil, Canada
NCT06340568
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
BioNTech SE
Registry updated 10 Nov 2026
Registry record: ClinicalTrials.govPhase 3277 sites
RecruitingArgentina, Austria, Australia, Belgium, Brazil, Canada
NCT06952504
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
Merck Sharp & Dohme LLC
Pre-treatment window Registry sentence: “Has received no prior systemic therapy for endometrial carcinoma except the following conditions as pre-specified by the protocol: 1 prior line of systemic platinum-based adjuvant and/or neoadjuvant chemotherapy in the setting of curative-intent, prior radiation with or without radiosensitizing chemotherapy if \>2 weeks before the start of induction treatment, or prior hormonal therapy for treatment of endometrial carcinoma that was discontinued ≥1 week before the start of induction treatment”
Registry updated 10 Nov 2026
Registry record: ClinicalTrials.govPhase 1/222 sites
RecruitingAustralia, Spain, France, United States
NCT07020221
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Verastem, Inc.
Registry updated 10 Nov 2026
Registry record: ClinicalTrials.govPhase 21 site
RecruitingUnited States
NCT01174121
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
National Cancer Institute (NCI)
Registry updated 9 Nov 2026
Registry record: ClinicalTrials.govPhase 2138 sites
RecruitingUnited States
NCT05112601
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
National Cancer Institute (NCI)
Registry updated 9 Nov 2026
Registry record: ClinicalTrials.govPhase 360 sites
RecruitingSouth Korea, United States
NCT05646316
Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
NRG Oncology
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govNo phase1 site
RecruitingBelgium
NCT07902375
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Universiteit Antwerpen
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 3309 sites
RecruitingUnited States
NCT07198074
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
National Cancer Institute (NCI)
Pre-treatment window Registry sentence: “NO prior chemotherapy for treatment of endometrial cancer OR”
Registry updated 6 Nov 2026
Registry record: ClinicalTrials.govPhase 121 sites
RecruitingSouth Korea, United States
NCT06586957
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
NiKang Therapeutics, Inc.
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 36 sites
RecruitingUnited States
NCT07867002
Assessing Survival Outcomes With Checkpoint Inhibition ExteNded vs Discontinued in Endometrial Cancer
UNC Lineberger Comprehensive Cancer Center
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 1/21 site
RecruitingUnited States
NCT06253494
Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
National Cancer Institute (NCI)
Registry updated 5 Nov 2026
Registry record: ClinicalTrials.govPhase 242 sites
RecruitingSpain, Georgia, South Korea, United States
NCT06695845
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Jazz Pharmaceuticals
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 210 sites
RecruitingUnited States
NCT04165772
Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors
Memorial Sloan Kettering Cancer Center
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 254 sites
RecruitingAustralia, Canada, Switzerland, China, Denmark, Spain
NCT06760819
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Bayer
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 125 sites
RecruitingAustralia, Spain, France, Italy, Japan, South Korea
NCT06400472
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Eli Lilly and Company
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 1/267 sites
RecruitingChina, Japan, South Korea, United States
NCT05579366
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Genmab
Registry updated 4 Nov 2026
Registry record: ClinicalTrials.govPhase 3173 sites
RecruitingAustralia, Belgium, Brazil, Canada, Germany, Denmark
NCT07166094
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
Genmab
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 111 sites
RecruitingBelgium, Spain, United States
NCT05856981
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Sairopa B.V.
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 344 sites
RecruitingArgentina, Australia, Brazil, Canada, United Kingdom, Israel
NCT07286331
A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01)
GlaxoSmithKline
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govPhase 312 sites
RecruitingCanada, Japan, South Korea
NCT07684599
A Study to Investigate Mocertatug Rezetecan as Maintenance Treatment for Participants With MMRp Endometrial Cancer (BEHOLD-Endometrial02)
GlaxoSmithKline
Registry updated 3 Nov 2026
Registry record: ClinicalTrials.govEarly Phase 16 sites
RecruitingAustralia
NCT06305962
177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
Radiopharm Theranostics, Ltd
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 16 sites
RecruitingUnited States
NCT07524322
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
Regor Pharmaceuticals Inc.
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 1/23 sites
RecruitingUnited States
NCT07909031
CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
Crescent Biopharma, Inc.
Registry updated 2 Nov 2026
Registry record: ClinicalTrials.govPhase 350 sites
RecruitingAustralia, China, Japan, Taiwan, United States
NCT07578649
Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer
Pfizer
Pre-treatment window Registry sentence: “Prior systemic therapy for first-line advanced or recurrent endometrial cancer.”
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.govPhase 1/245 sites
RecruitingAustria, Australia, Belgium, Germany, Spain, Finland
NCT07262619
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
Eikon Therapeutics
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.govPhase 11 site
RecruitingChina
NCT07715747
A Study to Evaluate the Safety,Pharmacokinetics,Pharmacodynamics,and Efficacy of TJ037130 in Adult Participants With Advanced Solid Tumors
TJ Biopharma Co., Ltd.
Registry updated 30 Oct 2026
Registry record: ClinicalTrials.govPhase 117 sites
RecruitingUnited States
NCT06774963
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
LigaChem Biosciences, Inc.
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.govPhase 21 site
Not yet recruitingCanada
NCT07516210
Adaptive Radiotherapy for Safe Hypofractionation
Centre hospitalier de l'Université de Montréal (CHUM)
Registry updated 29 Oct 2026
Registry record: ClinicalTrials.gov
The same sites as a list
- United States198 open trials
- China83 open trials
- Spain53 open trials
- Italy53 open trials
- France45 open trials
- Australia34 open trials
- Canada32 open trials
- South Korea32 open trials
- Germany29 open trials
- United Kingdom25 open trials
- Japan24 open trials
- Belgium22 open trials
- Netherlands18 open trials
- Poland18 open trials
- Taiwan14 open trials
- Denmark13 open trials
- Norway11 open trials
- Brazil10 open trials
- Türkiye10 open trials
- Finland10 open trials
- Israel9 open trials
- Argentina7 open trials
- Czechia7 open trials
- Greece6 open trials
- Sweden6 open trials
- Hungary6 open trials
- Singapore5 open trials
- Austria5 open trials
- Puerto Rico5 open trials
- Georgia4 open trials
- Ireland4 open trials
- Switzerland4 open trials
- Portugal4 open trials
- Thailand3 open trials
- Mexico3 open trials
- Lithuania3 open trials
- Colombia2 open trials
- New Zealand2 open trials
- Chile2 open trials
- India2 open trials
- Egypt2 open trials
- Peru1 open trial
- Panama1 open trial
- Romania1 open trial
- Estonia1 open trial
- Slovenia1 open trial
- Vietnam1 open trial
- Russia1 open trial
- Saudi Arabia1 open trial
- Indonesia1 open trial
Who treats this
Institutions with trials or publications in this disease (OpenAlex, registries). Institutions only, no people.
Florida Cancer Specialists & Research Institute
Port Charlotte, United States
1 trial · 13 publications · ROR
What changed in the last 7 days
Registry facts, one per line, newest first.
New in the registry
Improving Rural Endometrial Cancer Care
NCT07927244 · No phase · United States
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
Inavolisib for PIK3CA Mutated Advanced Endometrial Cancer: MITO END-4
NCT07522697 · Phase 2 · Italy
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
NCT07013851 · Phase 2 · Spain
Source: ClinicalTrials.govClosed for recruitment
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
NCT06607185 · Phase 1 · Belgium, Germany, Spain, France, Italy, Japan
Source: ClinicalTrials.govOpened for recruitment
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
NCT06515613 · Phase 1 · Spain, France, United Kingdom, United States
Source: ClinicalTrials.govClosed for recruitment
Neo-adjuvant Pembrolizumab as an Alternative Treatment for MMRd Uterine Cancer
NCT06180733 · Phase 2 · Netherlands
Source: ClinicalTrials.govClosed for recruitment
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
NCT06003231 · Phase 2 · Australia, Canada, Germany, Spain, France, United Kingdom
Source: ClinicalTrials.govPhase changed: Phase 1 → Phase 1/2
NCT05797168 · Phase 1/2 · Australia, Canada, China, Germany, Spain, United Kingdom
Source: ClinicalTrials.govClosed for recruitment
First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
NCT05527184 · Phase 1 · Australia, Belgium, Canada, Germany, Spain, France
Source: ClinicalTrials.govPhase changed: Phase 1/2 → Phase 1
First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
NCT05527184 · Phase 1 · Australia, Belgium, Canada, Germany, Spain, France
Source: ClinicalTrials.govClosed for recruitment
Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line
NCT05201547 · Phase 3 · Australia, Canada, Spain, France, United Kingdom, Italy
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT05143970 · Phase 1 · Belgium, France
Source: ClinicalTrials.govOpened for recruitment
NCT04300556 · Phase 1/2 · Spain, France, United Kingdom, Japan, United States
Source: ClinicalTrials.govStatus changed: Completed → Running, not recruiting
NCT04044859 · Phase 1 · Canada, Spain, United States
Source: ClinicalTrials.govClosed for recruitment
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
NCT04008797 · Phase 1/2 · Canada, China, Denmark, Spain, France, Italy
Source: ClinicalTrials.govOpened for recruitment
Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line
NCT05201547 · Phase 3 · Australia, Canada, Spain, France, United Kingdom, Italy
Source: ClinicalTrials.govOpened for recruitment
Neo-adjuvant Pembrolizumab as an Alternative Treatment for MMRd Uterine Cancer
NCT06180733 · Phase 2 · Netherlands
Source: ClinicalTrials.gov
Show more
Opened for recruitment
Inavolisib for PIK3CA Mutated Advanced Endometrial Cancer: MITO END-4
NCT07522697 · Phase 2 · Italy
Source: ClinicalTrials.govOpened for recruitment
First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
NCT05527184 · Phase 1 · Australia, Belgium, Canada, Germany, Spain, France
Source: ClinicalTrials.govStatus changed: Recruiting → Not yet recruiting
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
NCT06515613 · Phase 1 · Spain, France, United Kingdom, United States
Source: ClinicalTrials.govOpened for recruitment
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
NCT04008797 · Phase 1/2 · Canada, China, Denmark, Spain, France, Italy
Source: ClinicalTrials.govOpened for recruitment
A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
NCT06003231 · Phase 2 · Australia, Canada, Germany, Spain, France, United Kingdom
Source: ClinicalTrials.govClosed for recruitment
NCT04300556 · Phase 1/2 · Spain, France, United Kingdom, Japan, United States
Source: ClinicalTrials.govOpened for recruitment
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
NCT06607185 · Phase 1 · Belgium, Germany, Spain, France, Italy, Japan
Source: ClinicalTrials.gov
Results card
Trials that finished or stopped in the last 3 years, with the reason the registry gives and linked publications.
Phase 3Ended 26 Aug 2026
Completed262 participants
NCT02598219
Evaluation of Sentinel Node Policy in Early Stage Endometrial Carcinomas at Intermediate and High Risk of Recurrence.
Phase 2Ended 25 Aug 2026
Completed33 participants
NCT05634499
A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer
No phaseEnded 21 Aug 2026
Paused1000000 participants
NCT05506800
Guangzhou Women's Health Cohort Study (GWHCS)
Reason given: Due to the rebound of the COVID-19 epidemic in the city, we have to suspend the project temporarily.
Phase 1Ended 31 Jul 2026
No phaseEnded 16 Jul 2026
Withdrawn before start0 participants
NCT07226102
Virtual Mental Health Intervention to Address Fear of Progression for Women With High Risk or Stage III-IV Gynecologic or Breast Cancer
Reason given: slow accrual
Phase 1/2Ended 9 Jul 2026
No phaseEnded 24 Jun 2026
Completed19 participants
NCT03285152
A Study of Ketogenic Diet in Newly Diagnosed Overweight or Obese Endometrial Cancer Patients
Phase 1Ended 16 Jun 2026
Completed31 participants
NCT03586661
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase 2Ended 16 Jun 2026
Completed104 participants
2023-503905-12-00
Pembrolizumab Plus Lenvatinib in Combination with Belzutifan in Solid Tumors
Phase 2Ended 29 May 2026
Phase 1/2Ended Apr 2026
Withdrawn before start0 participants
NCT06385548
Efficacy and Safety Study of Lurbinectedin and Dostarlimab in Cancer Patients: Protocol VHIO21001 - LiDer
Reason given: IMP owner decision
No phaseEnded 28 Apr 2026
Completed202 participants
NCT07725159
Comparison of Lee-Huang Point and Umbilical Entry for Laparoscopic Success in Endometrial Cancer Patients
Phase 2Ended 24 Apr 2026
Completed26 participants
NCT05156268
A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma
No phaseEnded 17 Apr 2026
Phase 3Ended 9 Apr 2026
Completed10 participants
NCT05446324
SENtinel lymph node mapping with GAllium-68-tilmanocept PET/CT in high/high- intermediate risk endometrial cancer: a proof-of-concept study
No phaseEnded 27 Mar 2026
Completed755 participants
NCT04122235
The Lifestyle and Empowerment Techniques in Survivorship of Gynecologic Oncology Study
Phase 1/2Ended 25 Mar 2026
Stopped early179 participants
NCT05180474
GEN1047 for Solid Tumors - First in Human (FIH) Trial
Reason given: The Sponsor has made a strategic decision to stop the development of GEN1047.
No phaseEnded 20 Mar 2026
No phaseEnded 17 Mar 2026
Completed140 participants
NCT06973161
ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors
Phase 1Ended 17 Mar 2026
Stopped early85 participants
NCT05827614
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications
Reason given: Decision was made to halt the study based on overall clinical experience and market considerations. This decision was not driven by any safety signal.
Show more
Phase 2Ended 12 Mar 2026
Completed163 participants
NCT06036836
Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)
Phase 2Ended 12 Mar 2026
Completed27 participants
NCT03643510
Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer
Phase 2Ended 10 Mar 2026
Completed30 participants
NCT03694262
The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)
No phaseEnded 2 Mar 2026
Phase 2/3Ended 28 Feb 2026
Stopped early8 participants
NCT05316467
Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma
Reason given: no enough enrolled patients
Phase 2Ended 27 Feb 2026
Completed79 participants
NCT03617679
Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer
Phase 2Ended 4 Feb 2026
Completed62 participants
NCT01797523
A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma
No phaseEnded 3 Feb 2026
Completed80 participants
NCT06213571
Remote Home-Based Exercise Program for Strength Training in Endometrial Cancer Survivors in Rural Areas
No phaseEnded 1 Feb 2026
Withdrawn before start0 participants
NCT05390021
PET/MRI in Endometrial Cancer
Reason given: Unable to enroll patients to study
Early Phase 1Ended 31 Jan 2026
Withdrawn before start0 participants
NCT05289648
Niraparib in High-grade Endometrial Cancer Trial
Reason given: Unable to obtain funding
Phase 1Ended 9 Jan 2026
Stopped early17 participants
NCT06625515
First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
Reason given: The study was terminated by sponsor based on the adverse event profile.
No phaseEnded 5 Jan 2026
No phaseEnded 31 Dec 2025
Completed120 participants
NCT07372209
Effects and Safety of Oliceridine in Anesthesia Induction:A Randomised Controlled Trial
Phase 1/2Ended 30 Dec 2025
Completed19 participants
NCT06238687
A Study of STRO-002 in Chinese Adults With Epithelial Ovarian Cancer and Other Advanced Malignant Solid Tumors
Phase 1Ended 29 Dec 2025
Phase 1Ended 19 Dec 2025
Phase 2Ended 17 Dec 2025
Completed14 participants
NCT04719273
Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer
Phase 2Ended 12 Dec 2025
Stopped early7 participants
NCT05082025
Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
Reason given: Copanlisib development was discontinued by Bayer following withdrawal of copanlisib in relapsed follicular lymphoma in November 2023.
Phase 1Ended 3 Dec 2025
Stopped early78 participants
NCT03746431
A Phase 1 Study of [225Ac]-FPI-1434 Injection
Reason given: A strategic decision was made to discontinue the study and prioritize other programs within the portfolio. The study was not discontinued due to safety issues or adverse events related to FPI-1434, FPE-1547, or FPI-1175.
No phaseEnded 1 Dec 2025
No phaseEnded 1 Dec 2025
Completed86 participants
NCT04212910
Stratifying Endometrial Cancer Patients Using a PET/MRI Prognostic Model
Phase 2/3Ended 1 Dec 2025
Stopped early12 participants
NCT05454358
Letrozole as Maintenance Therapy for Post-surgical Endometrial Cancer Patients With NSMP
Reason given: No enough participants
No phaseEnded Nov 2025
Paused286 participants
NCT03095664
Effect of a Lifestyle Intervention on Nutritional Status and Prognosis of Endometrial Cancer Survivors
Reason given: Study stopped due to COVID-19 pandemic, as conducting a behaviour-change programme in groups was not recommended to prevent the spread of the virus.
Phase 4Ended 30 Nov 2025
Completed96 participants
NCT05651282
Risk Evaluation and Screening to Tailor Prevention and Reduce the Incidence of Endometrial Cancer
Phase 2Ended 30 Nov 2025
Stopped early71 participants
NCT05481645
Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.
Reason given: Per sponsor request. Premature closure was not prompted by any safety or efficacy concerns.
No phaseEnded 21 Nov 2025
No phaseEnded 17 Nov 2025
No phaseEnded 13 Oct 2025
Completed25 participants
NCT04386993
De-escalated Conformal Radiation Expedited Sequentially With Chemotherapy for Endometrial Cancer
No phaseEnded 5 Oct 2025
Completed63 participants
NCT06171945
Mobile Weight Loss Intervention for Adolescent and Young Adult Cancer Survivors
No phaseEnded 29 Sept 2025
No phaseEnded 29 Sept 2025
Completed603 participants
NCT04000880
Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health
No phaseEnded 28 Sept 2025
Completed23 participants
NCT06550791
Evaluating the Anticancer Learning Circle Lifestyle Program in Endometrial Cancer Survivors
No phaseEnded 26 Sept 2025
Phase 1Ended 20 Sept 2025
Paused131 participants
NCT05958199
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
Reason given: Business decision
No phaseEnded 15 Sept 2025
Completed323 participants
NCT04262180
Physical Activity Promotion for Breast and Endometrial Cancer Survivors
No phaseEnded 15 Sept 2025
Completed80 participants
NCT05191212
Real-time Lymphatic Channel Visualization Improves Bilateral Sentinel Lymph Node Detection in Endometrial Cancer
Phase 1Ended 11 Sept 2025
Stopped early26 participants
NCT06457997
A Study of PHN-010 in Patients With Advanced Solid Tumors
Reason given: The study was terminated by Sponsor for strategic reasons.
Phase 1/2Ended 18 Aug 2025
Stopped early33 participants
NCT06171789
PRO1107 in Patients With Advanced Solid Tumors
Reason given: Genmab has decided to discontinue the clinical development of GEN1107 as the overall benefit-risk profile no longer supports continuation
Phase 2Ended 14 Aug 2025
Phase 2/3Ended 7 Aug 2025
Stopped early5 participants
NCT06321068
BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer
Reason given: Due to the adjustment of our company's research and development strategy, we are now prematurely terminating this project.
Not medical advice. fetched 11 Nov 2026